Newly presented biomarker and clinical findings from the phase 2b PARADIGM trial of PrimeC informed the design of the global ...
Welcome to the Neurology News Network, my name is Louie Pasculli and here’s a look at some of the top stories in Neurology.
Assessing Long-Term Disease Control With Nipocalimab in Pediatric Generalized Myasthenia Gravis: Jonathan Strober, MD In a ...
Amanda L. Piquet, MD, reviews 1-year KYSA-8 findings, highlighting sustained clinical improvements and safety outcomes with ...
Two-year data from the phase 2 DAZALS trial showed a lower risk of death with dazucorilant 300 mg/day vs placebo in ALS, although the study did not meet its functional primary end point.
QurAlis reported interim ANQUR trial results showing target engagement, a biomarker signal, and a trend toward slower ...
Servier reported that sevasemten did not meet its primary or secondary endpoints in the pivotal GRAND CANYON trial for Becker ...
The president and founder of the Stuttering Treatment and Research Society (STARS) discussed highlights from the society's ...
CD19 and CD20 targeting reach different points along the B-cell lineage, creating distinct clinical questions about efficacy, onset, and patient selection in MG. Supported by Vor Bio Medical Affairs.
The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic discussed open-label extension data ...
The clinical professor of neurology and pediatrics at The Ohio State University Wexner Medical Center discussed payer step ...
IJMSC editor-in-chief, François Bethoux, MD, and colleagues cover idea generation, poster conversion, literature reviews, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results